Home News Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable_Oriental Fortune Net

Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable_Oriental Fortune Net

by admin
Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable_Oriental Fortune Net

Summary

[Xintian Pharmaceutical: The company’s product gross profit margin is relatively high and the impact of price increases of Chinese herbal medicines is relatively controllable]Xintian Pharmaceutical said during institutional research that in 2021, the company will achieve certain results in cost control, with a gross profit margin of 79.26%. On the one hand, initial results have been achieved by reducing costs and increasing efficiency, on the other hand, the company has a certain supply reserve of raw materials. At present, the company has not built its own medicinal material planting base. Regarding the construction of medicinal material planting base, relevant planning and arrangements will be made according to the actual situation. The company’s product gross profit margin is relatively high. Under the condition that the price of traditional Chinese medicinal materials continues to rise and the existing sales price remains unchanged, it is expected to have a certain impact on the company’s gross profit margin, but the impact is relatively controllable.


  Xintian PharmaceuticalexistInstitutional researchShi said that in 2021, the company will achieve certain results in cost control.interest rateIt was 79.26%. On the one hand, initial results were achieved in reducing costs and increasing efficiency, and on the other hand, the company had a certain supply of raw materials. At present, the company has not built its own medicinal material planting base. Regarding the construction of medicinal material planting base, relevant planning and arrangements will be made according to the actual situation.Company product grossinterest raterelatively high, intraditional Chinese medicineUnder the condition that the price of materials continues to rise and the existing sales price remains unchanged, it is expected to have a certain impact on the company’s gross profit margin, but the impact is relatively controllable.

See also  Shaanxi Province discloses the investigation and handling of the investigation and handling of the complaints of the masses assigned by the Third Central Ecological and Environmental Protection Supervision Team-West China Network (Shaanxi News Network)

(Article Source:securitiesTimes e company)


Article source: Securities Times · e company

Responsible editor: 65

Original title: Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable

Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.

report

Share to WeChat Moments

Open WeChat,

Click “Discover” at the bottom

Use “Sweep”

You can share the webpage to the circle of friends

Scan the QR code to follow

Oriental Fortune official website WeChat

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy